Viscosupplementation Companies
Viscosupplementation involves the injection of a lubricating substance into a joint to facilitate smoother movement and alleviate pain. This treatment is commonly used for individuals suffering from osteoarthritis.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Viscosupplementation Companies Update
OrthogenRx, Inc., a developer of viscosupplementation therapy for the relief of knee osteoarthritis (OA) pain, was acquired by Avanos Medical, Inc. for a reported $160 million. In addition to the $130 million paid at closing, the buyer will also be responsible for another $30 million in cash consideration that will be distributed upon the successful completion of certain growth milestones relating to the sales of the seller's commercial hyaluronic acid (HA) treatment products, GenVisc® 850 and TriVisc®. There is a potential market of $1 billion in the United States for the use of HA therapy to treat OA knee pain. GenVisc 850 and TriVisc are two new additions to Avanos' pain portfolio that have received FDA approval for the management of osteoarthritis knee pain in patients who have not found relief from more conventional treatments. Knee OA COOLIEF* therapy with cooled radiofrequency.
In a press release issued today, Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) doing business as Miravo Healthcare (Miravo or the Company) announced the commercial introduction of NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada. In September 2020, Health Canada gave the green light to the use of NeoVisc+ and NeoVisc ONE to alleviate pain and restore knee function in patients with degenerative (age-related) or mechanical (overuse) arthropathy. With the release of NeoVisc+ and NeoVisc ONE, medical professionals and patients now have access to cutting-edge choices for relieving knee pain.List of Viscosupplementation Key companies in the market
- Allergan
- Sanofi
- Hoffmann-La Roche
- Smith & Nephew Plc
- Zimmer Biomet
- Anika Therapeutics Inc.
- Ferring B.V.
- Bioventus
- FidiaFarmaceutici S.P.A.
Viscosupplementation Market Highlights:
Viscosupplementation Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
